Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Emerging Company Profile: Swiss biotech Unicyte is using donor-derived liver stem cells across a range of therapeutic areas, with its lead asset showing curative potential in urea cycle disorders.
TiumBio’s CEO shares his experiences as the original developer of hemophilia therapy Afstyla, the reason the rare disease-specialized company is exploring opportunities in Australia, as well as its R&D plans.
CEO Jan Schmidt-Brand tells Scrip that with another reliable long-term investor on the team alongside major shareholder Dievini, Heidelberg is well positioned to advance its amanitin-targeted antibody-drug conjugate candidates.
The head of the US arm of a major Korean government development institute talks to Scrip about why biotechs and pharma firms are flocking to Boston, how the organization is providing support and what the main challenges are.
PTC CEO Stuart Peltz tells Scrip that cost watchdogs are likely to look favorably on the firm’s transformational gene therapy for a distressing rare brain disorder in children who could not even lift their heads before treatment.
Ausbiotech's CEO and the Australian government’s Senior Trade and Investment Commissioner in South Korea talk to Scrip on the sidelines of the Bio Korea 2022 meeting about what makes Australia an attractive clinical trial destination for Korean and other foreign pharma firms, as well as about collaborations and other opportunities between the two countries.
Boryung’s chief technology officer outlines R&D strategy to move forward as a Korea-based global pharma firm and how domestic pharmas are juggling new drug development and generating cash cows.
The family-owned German group is the market leader in idiopathic pulmonary fibrosis with Ofev but the big-selling drug has significant side effects and only slows, but does not stop, the progression of the disease. It is hoping that the Phase III-ready compound BI 1015550 will offer a significant improvement.
Sanjiv Navangul, managing director and CEO, Bharat Serums and Vaccines, in a wide-ranging interview with Scrip, outlines the firm’s game plan to establish itself as a “force to reckon with” in women’s health - it goes beyond drugs and encompasses devices and potentially digital therapeutics as well. The former Janssen India chief also weighs in on the worrying industry-wide input cost escalation scenario and supply chain turbulence.
Emerging Company Profile: The British biotech, co-founded by experimental researcher Lady Amanda Feilding, is developing psychedelics therapeutics for a rare but debilitating headache disorder and mental health disorders.
Michael Parini talks to Scrip about how a new focus at the company can help it prove the value of its AAV-based gene therapy platform.
AstraZeneca's SGLT2 inhibitor Farxiga could soon get approval as an option for all heart failure patients following the success of the large Phase III DELIVER trial in people with preserved ejection fraction.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.